|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2710-2715.
Prepublished online as a Blood First Edition Paper on June 28, 2005; DOI 10.1182/blood-2005-04-1546.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
Nadine Martel,
James Lee, and
Philip S. Wells
From the University of Ottawa, Ottawa Health Research Institute, Ottawa, Ontario, Canada.
Heparin-induced thrombocytopenia (HIT) is an uncommon but potentially devastating complication of anticoagulation with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). Our objective was to determine and compare the incidences of HIT in surgical and medical patients receiving thromboprophylaxis with either UFH or LMWH. All relevant studies identified in the MEDLINE database (1984-2004), not limited by language, and from reference lists of key articles were evaluated. Randomized and nonrandomized controlled trials comparing prophylaxis with UFH and LMWH and measuring HIT or thrombocytopenia as outcomes were included. Two reviewers independently extracted data on thromboprophylaxis (type, dose, frequency, and duration), definition of thrombocytopenia, HIT assay, and rates of the following outcomes: HIT, thrombocytopenia, and thromboembolic events. HIT was defined as a decrease in platelets to less than 50% or to less than 100 x 109/L and positive laboratory HIT assay. Fifteen studies (7287 patients) were eligible: 2 randomized controlled trials (RCTs) measuring HIT (1014 patients), 3 prospective studies (1464 patients) with nonrandomized comparison groups in which HIT was appropriately measured in both groups, and 10 RCTs (4809 patients) measuring thrombocytopenia but not HIT. Three analyses were performed using a random effects model and favored the use of LMWH: (1) RCTs measuring HIT showed an odds ratio (OR) of 0.10 (95% confidence interval [CI], 0.01-0.2; P = .03); (2) prospective studies measuring HIT showed an OR of 0.10 (95% CI, 0.03-0.33; P < .001); (3) all 15 studies measured thrombocytopenia. The OR was 0.47 (95% CI, 0.22-1.02; P = .06). The inverse variance–weighted average that determined the absolute risk for HIT with LMWH was 0.2%, and with UFH the risk was 2.6%. Most studies were of patients after orthopedic surgery.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
HIT as a preventable disease?
- Theodore E. Warkentin
Blood 2005 106: 2600.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
E. A. Akl, I. Terrenato, M. Barba, F. Sperati, E. V. Sempos, P. Muti, D. J. Cook, and H. J. Schunemann
Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Thromboprophylaxis in Patients With Cancer: A Systematic Review and Meta-analysis
Arch Intern Med,
June 23, 2008;
168(12):
1261 - 1269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
340S - 380S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell
Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
381S - 453S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. F. Tapson
Acute Pulmonary Embolism
N. Engl. J. Med.,
March 6, 2008;
358(10):
1037 - 1052.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Kerendi, V. H. Thourani, J. D. Puskas, P. D. Kilgo, M. Osgood, R. A. Guyton, and O. M. Lattouf
Impact of Heparin-Induced Thrombocytopenia on Postoperative Outcomes After Cardiac Surgery
Ann. Thorac. Surg.,
November 1, 2007;
84(5):
1548 - 1555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher
So, Does Low-Molecular-Weight Heparin Cause Less Heparin-Induced Thrombocytopenia Than Unfractionated Heparin or Not?
Chest,
October 1, 2007;
132(4):
1108 - 1110.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Morris, S. Castrejon, G. Devendra, and A. C. Gamst
No Difference in Risk for Thrombocytopenia During Treatment of Pulmonary Embolism and Deep Venous Thrombosis With Either Low-Molecular-Weight Heparin or Unfractionated Heparin: A Metaanalysis
Chest,
October 1, 2007;
132(4):
1131 - 1139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Levy, K. A. Tanaka, and M. J. Hursting
Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia
Anesth. Analg.,
September 1, 2007;
105(3):
570 - 582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin and J. W. Eikelboom
Who Is (Still) Getting HIT?
Chest,
June 1, 2007;
131(6):
1620 - 1622.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Hutchison and I. Dasgupta
National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population
Nephrol. Dial. Transplant.,
June 1, 2007;
22(6):
1680 - 1684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Nutescu
Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches
Am. J. Health Syst. Pharm.,
June 1, 2007;
64(11_Supplement_7):
S5 - S13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Dentali, J. D. Douketis, M. Gianni, W. Lim, and M. A. Crowther
Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients
Ann Intern Med,
February 20, 2007;
146(4):
278 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Harrington and A. Jindeel
Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism
JAMA,
January 17, 2007;
297(3):
262 - 262.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Z. Goldhaber and M. Berkwits
Trials That Matter: Can Patients with Venous Thromboembolism Be Treated with Fixed-Dose Subcutaneous Unfractionated Heparin?
Ann Intern Med,
December 19, 2006;
145(12):
929 - 931.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin, J.-A. I. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
Blood,
November 1, 2006;
108(9):
2937 - 2941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Greinacher, M. Gopinadhan, J.-U. Gunther, M. A. Omer-Adam, U. Strobel, T. E. Warkentin, G. Papastavrou, W. Weitschies, and C. A. Helm
Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2006;
26(10):
2386 - 2393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin
Think of HIT When Thrombosis Follows Heparin.
Chest,
September 1, 2006;
130(3):
631 - 632.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Tardy, T. Lecompte, F. Boelhen, B. Tardy-Poncet, I. Elalamy, P. Morange, Y. Gruel, M. Wolf, D. Francois, E. Racadot, et al.
Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin
Blood,
September 1, 2006;
108(5):
1492 - 1496.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Arepally and T. L. Ortel
Heparin-Induced Thrombocytopenia
N. Engl. J. Med.,
August 24, 2006;
355(8):
809 - 817.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. W. Warkentin
Thrombotic End Point for Assessing Argatroban Therapy for Heparin-Induced Thrombocytopenia: Learning From Secondary Analyses of Prospective Studies
Chest,
June 1, 2006;
129(6):
1396 - 1398.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher
Unfractionated LMWH and the risk of HIT: are medical patients different?
Blood,
November 1, 2005;
106(9):
2931 - 2932.
[Full Text]
[PDF]
|
|
|
| |
